Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W24 AI medical record review for health insurance prior auth and claims; $3.1M from General Catalyst/DRW/YC deploying AI agents that process clinical documentation for coverage decisions competing with Cohere Health.
InQuery is a San Francisco-based AI healthcare platform — backed by Y Combinator (W24) with $3.1 million in total funding from Y Combinator, General Catalyst, Amino Capital, and DRW Venture Capital — providing health insurance companies and managed care organizations with AI agents that autonomously review medical records, analyze clinical documentation, and process prior authorization and claims decisions at a speed and scale that human reviewers cannot match. Founded in 2023, InQuery applies large language models trained on clinical documentation to the insurance review workflows that currently require teams of nurses and physician advisors to manually read through hundreds of pages of medical records per case.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.